Genetic medicines firm MeiraGTx misses Q3 revenue expectations, net loss widens

MeiraGTx Holdings

13/11/2025 13:12

Overview

MeiraGTx Q3 revenue misses analyst expectations, declining significantly from last year

Company enters strategic collaboration with Eli Lilly, including $75 mln upfront payment

Net loss widens to $50.5 mln in Q3, driven by increased R&D expenses

Outlook

Company anticipates Phase 2 data for AAV-hAQP1 in early 2027

MeiraGTx plans Phase 3 study for AAV-GAD in Parkinson's disease soon

Company expects riboswitch program to enter clinic for leptin deficiency

Result Drivers

R&D - The increase of $6.3 million was primarily due to an increase in manufacturing costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$410,000
$6.96 mln (5 Analysts)
Q3 EPS
-$0.62
Q3 Net Income
-$50.51 mln
Q3 Income from Operations
-$46.05 mln
Q3 Operating Expenses
$46.46 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for MeiraGTx Holdings PLC is $29.00, about 70.1% above its November 12 closing price of $8.66

Press Release: ID:nGNX3Mp2rM

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)